Bristol-Myers Squibb Stock Falls After Cancer Treatment Study Results Disappoint - Barron's

Bristol-Myers Squibb Stock Falls After Cancer Treatment Study Results Disappoint  Barron's

Bristol-Myers Squibb stock fell in after-hours trading on the back of disappointing data for a combination cancer treatment with its drugs Opdivo and Yervoy.